Impel NeuroPharma presented patient-reported outcomes data from the company's pivotal phase III, open-label study "STOP 301" of INP104 (dihydroergotamine mesylate) using the company's proprietary POD technology, for the treatment of acute migraine. Yourway is committed to supporting clinical trials for unmet medical needs.